Free Trial

Reata Pharmaceuticals (RETA) News Today

Notice: This company has been marked as potentially delisted and may not be actively trading.
Braun Stacey Associates Inc. Lowers Stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
Braun Stacey Associates Inc. cut its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 47.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 164,775 shares of the company's stock after selling 146,235 shares during the pe
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Consensus Recommendation of "Hold" by Brokerages
Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Get Free Report) has been given a consensus rating of "Hold" by the thirteen ratings firms that are covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a hold recommendation and four have issued a buy recommendatio
Top Growth Stocks for October 2023
Biogen Completes Acquisition of Reata Pharmaceuticals
First Light Asset Management LLC Sells 475,525 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
First Light Asset Management LLC decreased its holdings in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 23.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,586,928 shares of the
HighTower Advisors LLC Decreases Position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
HighTower Advisors LLC trimmed its position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 6.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 48,978 shares of the company's stock after s
Credit Suisse AG Purchases 2,334 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
Credit Suisse AG boosted its position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 6.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 41,476 shares of the company's stock after purchasing an additional 2,334 share
Swiss National Bank Reduces Stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
Swiss National Bank reduced its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 10.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,200 shares of the company's stock afte
3,204 Shares in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Purchased by Pictet Asset Management SA
Pictet Asset Management SA bought a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 3,204 shares of the company's stock, valued at approximately $291,000. Several
Reata Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RETA)
Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Get Free Report) was the recipient of some unusual options trading activity on Friday. Investors acquired 5,018 put options on the company. This is an increase of 180% compared to the typical volume of 1,794 put options.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Receives Consensus Recommendation of "Hold" from Analysts
Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Get Free Report) has been given an average recommendation of "Hold" by the thirteen research firms that are currently covering the stock, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation and four have ass
US Bancorp DE Purchases 8,947 Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
US Bancorp DE lifted its position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 1,280.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,646 shares of the company's stock after purchasing an additional 8,947 shares d
StockNews.com Initiates Coverage on Reata Pharmaceuticals (NASDAQ:RETA)
StockNews.com began coverage on shares of Reata Pharmaceuticals in a research note on Wednesday. They issued a "sell" rating for the company.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank
Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 23.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,497 shares of the company's stock after
Cantor Fitzgerald Reiterates "Neutral" Rating for Reata Pharmaceuticals (NASDAQ:RETA)
Cantor Fitzgerald reissued a "neutral" rating and set a $172.00 price objective on shares of Reata Pharmaceuticals in a report on Tuesday.
Biondo Investment Advisors LLC Takes $323,000 Position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
Biondo Investment Advisors LLC purchased a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,550 shares of the company's stock, valued at approximately $323,000. A number of other
Reata Pharmaceuticals (RETA) Gets a Hold from Barclays
Reata Pharmaceuticals (NASDAQ:RETA) Earns Sell Rating from Analysts at StockNews.com
StockNews.com initiated coverage on Reata Pharmaceuticals in a research report on Monday. They set a "sell" rating for the company.
Equities Analysts Issue Forecasts for Reata Pharmaceuticals, Inc.'s Q2 2025 Earnings (NASDAQ:RETA)
Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) - Research analysts at Zacks Research boosted their Q2 2025 EPS estimates for shares of Reata Pharmaceuticals in a research note issued on Wednesday, August 2nd. Zacks Research analyst S. Ganoria now anticipates that the company will post ea
Integrated Wealth Concepts LLC Purchases Shares of 11,294 Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
Integrated Wealth Concepts LLC bought a new position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 11,294 shares of the company's stock, valued at approxima
Citigroup Downgrades Reata Pharmaceuticals (NASDAQ:RETA) to Neutral
Citigroup downgraded Reata Pharmaceuticals from a "buy" rating to a "neutral" rating in a research note on Tuesday.
Reata Pharmaceuticals (NASDAQ:RETA) Stock Rating Lowered by SVB Securities
SVB Securities cut Reata Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Friday.
Biogen to Acquire Reata Pharmaceuticals
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
Expert Ratings for Reata Pharmaceuticals
5,396 Shares in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Bought by Raymond James Financial Services Advisors Inc.
Raymond James Financial Services Advisors Inc. bought a new stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Shares Sold by DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale reduced its stake in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) by 24.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,000 share
Moody Aldrich Partners LLC Invests $4.50 Million in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)
Moody Aldrich Partners LLC bought a new position in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 49,529 shares of the company's stock, valued at approximately $
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA - Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and eight hav
Get Reata Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.

The Presidential candidate you should REALLY be worried about (Ad)

The Presidential candidate you should REALLY be worried about Most Americans are overlooking the seemingly impossible candidate that should worry you. It's not Biden… Trump… Newsom… or even Michelle. It's someone even worse. New evidence of a secret plan indicates he could soon return, and finish what he started.

Get the full story right here.

RETA Media Mentions By Week

RETA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RETA
News Sentiment

0.00

0.44

Average
Medical
News Sentiment

RETA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RETA Articles
This Week

0

1

RETA Articles
Average Week

Get Reata Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:RETA) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners